The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...

Middle-aged adults with long-term fluctuations in blood pressure may face a higher risk for sudden cardiac death than their ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Ablation is a minimally invasive procedure to treat abnormal electrical short circuits caused by a heart attack. These ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

A debate over a proposal to allow cannabis lounges in the city of Sacramento resumes this week, with council members set to ...

Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both did not improve atrial ...

Alva Health is developing a device that uses noninvasive wearables and AI/ML algorithms to monitor the onset of stroke ...